메뉴 건너뛰기




Volumn 174, Issue , 2016, Pages 120-128

A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; DABIGATRAN; INOTROPIC AGENT; PLACEBO; RIVAROXABAN; TICAGRELOR; TICLOPIDINE; WARFARIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST;

EID: 84977674940     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.01.004     Document Type: Article
Times cited : (27)

References (46)
  • 1
    • 84971619896 scopus 로고    scopus 로고
    • ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
    • [1] Roffi, M., Patrono, C., Collet, J.P., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 3 (2016), 267–315.
    • (2016) Eur Heart J , vol.3 , pp. 267-315
    • Roffi, M.1    Patrono, C.2    Collet, J.P.3
  • 2
    • 84866732231 scopus 로고    scopus 로고
    • ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
    • [2] Steg, P.G., James, S.K., Atar, D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 (2012), 2569–2619.
    • (2012) Eur Heart J , vol.33 , pp. 2569-2619
    • Steg, P.G.1    James, S.K.2    Atar, D.3
  • 3
    • 84920278525 scopus 로고    scopus 로고
    • AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines
    • [3] Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 130 (2014), e344–e426.
    • (2014) Circulation , vol.130 , pp. e344-e426
    • Amsterdam, E.A.1    Wenger, N.K.2    Brindis, R.G.3
  • 4
    • 84872698656 scopus 로고    scopus 로고
    • ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines
    • [4] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 61 (2013), e78–e140.
    • (2013) J Am Coll Cardiol , vol.61 , pp. e78-e140
    • O'Gara, P.T.1    Kushner, F.G.2    Ascheim, D.D.3
  • 5
    • 49749120012 scopus 로고    scopus 로고
    • Prevalence, predictors, and impact of conservative medical management for patients with non–ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease
    • [5] Chan, M.Y., Mahaffey, K.W., Sun, L.J., et al. Prevalence, predictors, and impact of conservative medical management for patients with non–ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv 1 (2008), 369–378.
    • (2008) JACC Cardiovasc Interv , vol.1 , pp. 369-378
    • Chan, M.Y.1    Mahaffey, K.W.2    Sun, L.J.3
  • 6
    • 67650556158 scopus 로고    scopus 로고
    • The paradoxical use of cardiac catheterization in patients with non–ST-elevation acute coronary syndromes: lessons from the can rapid stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) quality improvement initiative
    • [6] Cohen, M.G., Filby, S.J., et al. The paradoxical use of cardiac catheterization in patients with non–ST-elevation acute coronary syndromes: lessons from the can rapid stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) quality improvement initiative. Am Heart J 158 (2009), 263–270.
    • (2009) Am Heart J , vol.158 , pp. 263-270
    • Cohen, M.G.1    Filby, S.J.2
  • 7
    • 80052162121 scopus 로고    scopus 로고
    • Apixaban with antiplatelet therapy after acute coronary syndrome
    • [7] Alexander, J.H., Lopes, R.D., James, S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365 (2011), 699–708.
    • (2011) N Engl J Med , vol.365 , pp. 699-708
    • Alexander, J.H.1    Lopes, R.D.2    James, S.3
  • 8
    • 80052232522 scopus 로고    scopus 로고
    • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    • [8] Oldgren, J., Budaj, A., Granger, C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32 (2011), 2781–2789.
    • (2011) Eur Heart J , vol.32 , pp. 2781-2789
    • Oldgren, J.1    Budaj, A.2    Granger, C.B.3
  • 9
    • 80054733922 scopus 로고    scopus 로고
    • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor XA inhibitor darexaban (YM150) following acute coronary syndrome
    • [9] Steg, P.G., Mehta, S.R., Jukema, J.W., et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor XA inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32 (2011), 2541–2554.
    • (2011) Eur Heart J , vol.32 , pp. 2541-2554
    • Steg, P.G.1    Mehta, S.R.2    Jukema, J.W.3
  • 10
    • 83655177669 scopus 로고    scopus 로고
    • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    • [10] Tricoci, P., Huang, Z., Held, C., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366 (2012), 20–33.
    • (2012) N Engl J Med , vol.366 , pp. 20-33
    • Tricoci, P.1    Huang, Z.2    Held, C.3
  • 11
    • 67649562905 scopus 로고    scopus 로고
    • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    • [11] Mega, J.L., Braunwald, E., Mohanavelu, S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374 (2009), 29–38.
    • (2009) Lancet , vol.374 , pp. 29-38
    • Mega, J.L.1    Braunwald, E.2    Mohanavelu, S.3
  • 12
    • 84862907587 scopus 로고    scopus 로고
    • Rivaroxaban in patients with a recent acute coronary syndrome
    • [12] Mega, J.L., Braunwald, E., Wiviott, S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
    • (2012) N Engl J Med , vol.366 , pp. 9-19
    • Mega, J.L.1    Braunwald, E.2    Wiviott, S.D.3
  • 13
    • 84913619061 scopus 로고    scopus 로고
    • ESC/EACTS guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
    • [13] Windecker, S., Kolh, P., Alfonso, F., et al. ESC/EACTS guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35 (2014), 2541–2619.
    • (2014) Eur Heart J , vol.35 , pp. 2541-2619
    • Windecker, S.1    Kolh, P.2    Alfonso, F.3
  • 14
    • 0015956225 scopus 로고
    • A randomized controlled trial of acetyl salicyclic acid in the secondary prevention of mortality from myocardial infarction
    • [14] Elwood, P.C., Cochrane, A.L., Burr, M.L., et al. A randomized controlled trial of acetyl salicyclic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1 (1974), 436–440.
    • (1974) Br Med J , vol.1 , pp. 436-440
    • Elwood, P.C.1    Cochrane, A.L.2    Burr, M.L.3
  • 15
    • 0023805341 scopus 로고
    • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
    • [15] Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332 (1988), 349–360.
    • (1988) Lancet , vol.332 , pp. 349-360
  • 16
    • 0025090942 scopus 로고
    • Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
    • [16] Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990), 827–830.
    • (1990) Lancet , vol.336 , pp. 827-830
  • 17
    • 0026042937 scopus 로고
    • Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization
    • [17] Wallentin, L.C., Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 18 (1991), 1587–1593.
    • (1991) J Am Coll Cardiol , vol.18 , pp. 1587-1593
    • Wallentin, L.C.1
  • 18
    • 0032481092 scopus 로고    scopus 로고
    • A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
    • [18] Leon, M.B., Baim, D.S., Popma, J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998), 1665–1671.
    • (1998) N Engl J Med , vol.339 , pp. 1665-1671
    • Leon, M.B.1    Baim, D.S.2    Popma, J.J.3
  • 19
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • [19] Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
    • (2001) N Engl J Med , vol.345 , pp. 494-502
  • 20
    • 3242770664 scopus 로고    scopus 로고
    • Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
    • [20] Diener, H.C., Bogousslavsky, J., Brass, L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004), 331–337.
    • (2004) Lancet , vol.364 , pp. 331-337
    • Diener, H.C.1    Bogousslavsky, J.2    Brass, L.M.3
  • 21
    • 73949157474 scopus 로고    scopus 로고
    • Platelet thrombin receptor antagonism and atherothrombosis
    • [21] Angiolillo, D.J., Capodanno, D., Goto, S., Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31 (2010), 17–28.
    • (2010) Eur Heart J , vol.31 , pp. 17-28
    • Angiolillo, D.J.1    Capodanno, D.2    Goto, S.3
  • 22
    • 0034068625 scopus 로고    scopus 로고
    • The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
    • [22] Sugidachi, A., Asai, F., Ogawa, T., et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 (2000), 1439–1446.
    • (2000) Br J Pharmacol , vol.129 , pp. 1439-1446
    • Sugidachi, A.1    Asai, F.2    Ogawa, T.3
  • 23
    • 0141924393 scopus 로고    scopus 로고
    • Coagulation activation and long-term outcome in acute coronary syndromes
    • [23] Ardissino, D., Merlini, P.A., Bauer, K.A., et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 102 (2003), 2731–2735.
    • (2003) Blood , vol.102 , pp. 2731-2735
    • Ardissino, D.1    Merlini, P.A.2    Bauer, K.A.3
  • 24
    • 0028356326 scopus 로고
    • Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
    • [24] Merlini, P.A., Bauer, K.A., Oltrona, L., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90 (1994), 61–68.
    • (1994) Circulation , vol.90 , pp. 61-68
    • Merlini, P.A.1    Bauer, K.A.2    Oltrona, L.3
  • 25
    • 78149487486 scopus 로고    scopus 로고
    • Effect of rivaroxaban on markers of coagulation in patients with acute coronary syndromes: an ATLAS ACS-TIMI 46 substudy
    • [25] Gibson, C.M., Mega, J.L., Jennings, L.H., et al. Effect of rivaroxaban on markers of coagulation in patients with acute coronary syndromes: an ATLAS ACS-TIMI 46 substudy. Circulation, 120, 2009, S1035.
    • (2009) Circulation , vol.120 , pp. S1035
    • Gibson, C.M.1    Mega, J.L.2    Jennings, L.H.3
  • 26
    • 84943648606 scopus 로고    scopus 로고
    • Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies
    • [26] Perzborn, E., Heitmeier, S., Laux, V., Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 20 (2015), 554–562.
    • (2015) J Cardiovasc Pharmacol Ther , vol.20 , pp. 554-562
    • Perzborn, E.1    Heitmeier, S.2    Laux, V.3
  • 27
    • 84875720372 scopus 로고    scopus 로고
    • Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
    • [27] Dewilde, W.J., Oirbans, T., Verheugt, F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
    • (2013) Lancet , vol.381 , pp. 1107-1115
    • Dewilde, W.J.1    Oirbans, T.2    Verheugt, F.W.3
  • 28
    • 84937636231 scopus 로고    scopus 로고
    • Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy with Warfarin in Patients with AF that Undergo a PCI with Stenting (REDUAL-PCI): NCT02164864
    • ClinicalTrials.gov Web site [Updated September 15, 2015, Accessed October 5, 2015]
    • [28] Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy with Warfarin in Patients with AF that Undergo a PCI with Stenting (REDUAL-PCI): NCT02164864. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT02164864 [Updated September 15, 2015, Accessed October 5, 2015].
  • 29
    • 84977643346 scopus 로고    scopus 로고
    • Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients with Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention (AUGUSTUS): NCT02415400
    • ClinicalTrials.gov Web site [Updated October 1, 2015, Accessed October 5, 2015]
    • [29] Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients with Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention (AUGUSTUS): NCT02415400. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT02415400?term=NCT02415400&rank=1 [Updated October 1, 2015, Accessed October 5, 2015].
  • 30
    • 84927573989 scopus 로고    scopus 로고
    • An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)
    • [30] Gibson, C.M., Mehran, R., Bode, C., et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 169 (2015), 472–478.
    • (2015) Am Heart J , vol.169 , pp. 472-478
    • Gibson, C.M.1    Mehran, R.2    Bode, C.3
  • 31
    • 84891899155 scopus 로고    scopus 로고
    • GLOBAL LEADERS: a clinical study comparing two forms of anti-platelet therapy after stent implantation: NCT01813435
    • ClinicalTrials.gov Web site [Updated July 21, 2015, Accessed October 5, 2015]
    • [31] GLOBAL LEADERS: a clinical study comparing two forms of anti-platelet therapy after stent implantation: NCT01813435. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT01813435?term=NCT01813435&rank=1 [Updated July 21, 2015, Accessed October 5, 2015].
  • 32
    • 84977616984 scopus 로고    scopus 로고
    • Ticagrelor with Aspirin or Alone in High-risk Patients after Coronary Intervention (TWILIGHT): NCT02270242
    • ClinicalTrials.gov Web site [Updated September 8, 2015, Accessed October 5, 2015]
    • [32] Ticagrelor with Aspirin or Alone in High-risk Patients after Coronary Intervention (TWILIGHT): NCT02270242. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT02270242?term=nct02270242&rank=1 [Updated September 8, 2015, Accessed October 5, 2015].
  • 33
    • 84918772240 scopus 로고    scopus 로고
    • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
    • [33] Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
    • (2014) N Engl J Med , vol.371 , pp. 2155-2166
    • Mauri, L.1    Kereiakes, D.J.2    Yeh, R.W.3
  • 34
    • 84929884068 scopus 로고    scopus 로고
    • Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials
    • [34] Giustino, G., Baber, U., Sartori, S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
    • (2015) J Am Coll Cardiol , vol.65 , pp. 1298-1310
    • Giustino, G.1    Baber, U.2    Sartori, S.3
  • 35
    • 0037065502 scopus 로고    scopus 로고
    • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
    • [35] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
    • (2002) BMJ , vol.324 , pp. 71-86
  • 36
    • 34248352504 scopus 로고    scopus 로고
    • Aspirin dose for the prevention of cardiovascular disease: a systematic review
    • [36] Campbell, C.L., Smyth, S., Montalescot, G., et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007), 2018–2024.
    • (2007) JAMA , vol.297 , pp. 2018-2024
    • Campbell, C.L.1    Smyth, S.2    Montalescot, G.3
  • 37
    • 34247558672 scopus 로고    scopus 로고
    • Clinical end points in coronary stent trials: a case for standardized definitions
    • [37] Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
    • (2007) Circulation , vol.115 , pp. 2344-2351
    • Cutlip, D.E.1    Windecker, S.2    Mehran, R.3
  • 38
    • 85058721877 scopus 로고    scopus 로고
    • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET-AT study
    • [38] The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators, Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET-AT study. Am Heart J 159 (2010), 340–347.
    • (2010) Am Heart J , vol.159 , pp. 340-347
    • The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators,1
  • 39
    • 79959550517 scopus 로고    scopus 로고
    • Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium
    • [39] Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123 (2011), 2736–2747.
    • (2011) Circulation , vol.123 , pp. 2736-2747
    • Mehran, R.1    Rao, S.V.2    Bhatt, D.L.3
  • 40
    • 84867577224 scopus 로고    scopus 로고
    • Third universal definition of myocardial infarction
    • [40] Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. Circulation 126 (2012), 2020–2035.
    • (2012) Circulation , vol.126 , pp. 2020-2035
    • Thygesen, K.1    Alpert, J.S.2    Jaffe, A.S.3
  • 41
    • 84937681428 scopus 로고    scopus 로고
    • 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trialsa report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards)
    • [41] Hicks, K.A., Tcheng, J.E., Bozkurt, B., et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trialsa report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol 66 (2015), 403–469.
    • (2015) J Am Coll Cardiol , vol.66 , pp. 403-469
    • Hicks, K.A.1    Tcheng, J.E.2    Bozkurt, B.3
  • 42
    • 9244251971 scopus 로고    scopus 로고
    • A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
    • [42] Schömig, A., Neumann, F.J., Kastrati, A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996), 1084–1089.
    • (1996) N Engl J Med , vol.334 , pp. 1084-1089
    • Schömig, A.1    Neumann, F.J.2    Kastrati, A.3
  • 43
    • 0031035542 scopus 로고    scopus 로고
    • Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy
    • [43] Schömig, A., Neumann, F.J., Walter, H., et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 29 (1997), 28–34.
    • (1997) J Am Coll Cardiol , vol.29 , pp. 28-34
    • Schömig, A.1    Neumann, F.J.2    Walter, H.3
  • 44
    • 7844220998 scopus 로고    scopus 로고
    • Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study
    • [44] Bertrand, M., Legrand, V., Boland, J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 98 (1998), 1597–1603.
    • (1998) Circulation , vol.98 , pp. 1597-1603
    • Bertrand, M.1    Legrand, V.2    Boland, J.3
  • 45
    • 0032542028 scopus 로고    scopus 로고
    • Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
    • [45] Urban, P., Macaya, C., Rupprecht, H.J., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 (1998), 2126–2132.
    • (1998) Circulation , vol.98 , pp. 2126-2132
    • Urban, P.1    Macaya, C.2    Rupprecht, H.J.3
  • 46
    • 84937622243 scopus 로고    scopus 로고
    • Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V coronary stent system trials
    • [pii:e001362, PMID: 25940520]
    • [46] Généreux, P., Rutledge, D.R., Palmerini, T., et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V coronary stent system trials. Circ Cardiovasc Interv, 8, 2015, 10.1161/CIRCINTERVENTIONS.114.001362 [pii:e001362, PMID: 25940520].
    • (2015) Circ Cardiovasc Interv , vol.8
    • Généreux, P.1    Rutledge, D.R.2    Palmerini, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.